Bindinglaw

US · guidance

CMS SOM App. H, Tag V118

CDC RR-05 as Adopted by Reference 42 CFR 494.30(a)(1)(i)

activein force · 2026-07-22 – presentas-observed

Intravenous medication vials labeled for single use, including erythropoietin, should not be

punctured more than once.

Interpretive Guidance § 494.30(a)(1)(i)

Page 13 of 420

According to the CDC, once a needle has entered a vial labeled for single use, the sterility of the

product can no longer be guaranteed. Residual medication from two or more vials should not be

pooled into a single vial.

Single-use vials/ampules must be used for only one patient, should not be entered more than

once, and if entered, may not be stored for future use.

Staff should only enter vials with a new sterile syringe and needle. If both vials are single-use

and are discarded after the single entry into each, the same syringe may be used. If either vial is

multi-use, a different syringe must be used for entry into each vial.

History

Rev.

Provenance

Source
cms.gov
Retrieved
2026-07-22
Edition
som-2026-07-22
Content hash
d0d579274846d83082b5b2fd8875fde0fbca24146f9a191f281780eab223379d
View the official source →

The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.

Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.

Coverage · API docs

Bindinglaw

Point-in-time US law with the receipt attached. Source URL, retrieval time, content hash, and validity dates on every answer.

curl api.binding.law/v1/law/coverage

© 2026 binding.law · a Jubal, Inc. productAttorneys and firms never pay. Ever.